Madryn Asset Management DFAN14AAdditional proxy materials by non-management

Exhibit 1 The Case for Voting AGAINST the SLGC-LAB Proposed Merger

Legal Disclaimer The views expressed in this presentation (the Presentation ) represent the opinions of Madryn Asset Management, LP ( Madryn Asset Management and collectively with its affiliates, Madryn ). The Presentation is for informational purposes only, and it does not have regard to the specific investment objective, financial situation, suitability or particular need of any specific person who may receive the Presentation, and should not be taken as advice on the merits of any investment decision. The views expressed in the Presentation represent the opinions of Madryn, and are based on publicly available information and Madryn's analyses. Certain financial information and data used in the Presentation has been derived or obtained from filings made with the U.S. Securities and Exchange Commission (the SEC ) by SomaLogic, Inc. ( SomaLogic, “SLGC” or the Company ), Standard BioTools Inc. ( LAB or Standard ) or other companies that Madryn considers comparable, as well as from third party sources. Madryn has not sought or obtained consent from any third party to use any statements or information indicated in the Presentation as having been obtained or derived from a third party. Any such statements or information should not be viewed as indicating support of such third party for the views expressed in the Presentation. Information contained in the Presentation has not been independently verified by Madryn. Madryn disclaims any obligation to correct or update the Presentation or to otherwise provide any additional materials. Madryn recognizes that SomaLogic and Standard may possess confidential information that could lead them to disagree with Madryn's views and/or conclusions. Madryn currently beneficially owns, and/or has an economic interest in, shares of SomaLogic. Madryn is in the business of trading—buying and selling—securities. Madryn may buy or sell or otherwise change the form or substance of any of its investments in any manner permitted by law and expressly disclaims any obligation to notify any recipient of the Presentation of any such changes. There may be developments in the future that cause Madryn to engage in transactions that change its beneficial ownership and/or economic interest in the Company. The securities or investment ideas listed are not presented in order to suggest or show profitability of any or all transactions. There should be no assumption that any specific portfolio securities identified and described in the Presentation were or will be profitable. Under no circumstances is the Presentation to be used or considered as an offer to sell or a solicitation of an offer to buy any security. This document is the property of Madryn and may not be published without the express written consent of Madryn. All registered or unregistered service marks, trademarks and trade names referred to in the Presentation are the property of their respective owners, and Madryn's use herein does not imply an affiliation with, or endorsement by, the owners of these service marks, trademarks and trade names. The information herein contains forward-looking statements. Specific forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and include, without limitation, words such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “seeks,” “could,” “should” or the negative of such terms or other variations on such terms or comparable terminology. Similarly, statements that describe our objectives, plans or goals are forward-looking. Forward-looking statements are subject to various risks and uncertainties and assumptions. There can be no assurance that any idea or assumption herein is, or will be proven, correct. If one or more of the risks or uncertainties materialize, or if Madryn's underlying assumptions prove to be incorrect, the actual results may vary materially from outcomes indicated by these statements. Accordingly, forward-looking statements should not be regarded as a representation by Madryn that the future plans, estimates or expectations contemplated will ever be achieved. CERTAIN INFORMATION CONCERNING THE PARTICIPANTS MADRYN STRONGLY ADVISES ALL STOCKHOLDERS OF SOMALOGIC TO READ THE DEFINITIVE PROXY STATEMENT, THE ACCOMPANYING GREEN PROXY CARD AND OTHER DOCUMENTS RELATED TO THE SOLICITATION OF PROXIES BY THE PARTICIPANTS, AS THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ADDITIONAL INFORMATION RELATED TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS IN SOMALOGIC, BY SECURITY HOLDINGS OR OTHERWISE. The participants in the proxy solicitation are Madryn Asset Management, Madryn Health Partners, LP, Madryn Health Partners (Cayman Master), LP, Madryn Health Advisors, LP, Madryn Health Advisors GP, LLC, Madryn Select Opportunities, LP, Madryn Select Advisors, LP, Madryn Select Advisors GP, LLC and Avinash Amin (the Participants ). The Participants have filed with the SEC a definitive proxy statement and accompanying GREEN Proxy Card to be used in connection with the solicitation of proxies from SomaLogic's shareholders for the special meeting of shareholders. As of the date hereof, Madryn Asset Management beneficially owns an aggregate of 7,879,073 shares of common stock, $0.0001 par value per share of SomaLogic (“Common Stock”), Madryn Health Partners, LP beneficially owns an aggregate of 2,763,604 shares of Common Stock, Madryn Health Partners (Cayman Master), LP beneficially owns an aggregate of 4,705,598 shares of Common Stock, Madryn Health Advisors, LP beneficially owns an aggregate of 7,469,202 shares of Common Stock, Madryn Health Advisors GP, LLC beneficially owns an aggregate of 7,469,202 shares of Common Stock, Madryn Select Opportunities, LP beneficially owns an aggregate of 409,871 shares of Common Stock, Madryn Select Advisors, LP beneficially owns beneficially owns an aggregate of 409,871 shares of Common Stock, Madryn Select Advisors GP, LLC beneficially owns an aggregate of 409,871 shares of Common Stock and Avinash Amin beneficially owns an aggregate of 7,879,073 shares of Common Stock. Collectively, the Participants own an aggregate of 7,879,073 shares of Common Stock. MADRYN ASSET MANAGEMENT 2

Table of Contents Section I: Executive Summary Page 5 Section II: The Proposed Merger Materially Undervalues SLGC Page 18 Section III: The Proposed Merger Is the Result of a Deeply Page 28 Flawed and Conflicted Process Section IV: SLGC Has Far Superior Prospects, Including as a Page 43 Standalone Company MADRYN ASSET MANAGEMENT 3

I. Executive Summary

Why We Are Here Merger Drastically Process Was Deeply There Are Far Superior Undervalues SomaLogic Flawed and Conflicted Alternatives for SomaLogic • SomaLogic’s equity, measured in several • The basis upon which the process was • SLGC’s continued operational re- launched is deeply flawed – SomaLogic has independent ways, is worth substantially organization, commercial execution and plenty of runway, and transacting now only more than the deal consideration, ongoing R&D efforts can create value for solidifies its historically low valuation especially when considering the recently shareholders; permanent management announced acquisition of Olink Holding should be installed • The transaction structure clearly benefits AB (publ) (“Olink” or “OLK”) Casdin Capital through a non-traditional, • The distributed kit product launch with pro-forma capital structure • The deal price is based on historically low Illumina, Inc. (“Illumina” or “ILMN”) can SomaLogic share prices be transformative for the Company from a • Whether explicitly directed or not, revenue and growth perspective and the SomaLogic’s transaction committee (the • According to PitchBook, SomaLogic has Company should seek to realize that value SomaLogic Transaction Committee or raised a collective $1.26bn since its on a standalone basis SLGC Transaction Committee ) was clearly founding but SomaLogic's board of not independent and has incentives to directors (the Board ) has recommended • The mid-to-high-plex proteomics market is structure a deal that benefits Casdin Capital a merger with Standard (the Proposed in its infancy and SLGC will continue to • The merger process has unexplained gaps Merger ) that values SomaLogic equity benefit on a standalone basis from that and shows that SomaLogic did not fulsomely value near its cash balance, implying little tailwind evaluate all potential alternatives to no enterprise value • There is no operational downside to SLGC • SomaLogic's financial advisor stipulates it • The value of the consideration declined if it does not consummate the merger; expects to receive future business from significantly prior to the announcement of SLGC is a scarce asset and can likely fetch Casdin Capital, providing it with an incentive the OLK acquisition, implying the market a strong valuation in the future to render a fair opinion for the transaction did not like the transaction ___________________________________________________________ MADRYN ASSET MANAGEMENT 5 Source: Capital IQ, FactSet, Pitchbook, SomaLogic public filings, and publicly available equity research.

About Madryn Asset Management Madryn Asset Management, LP (“Madryn”) is a leading alternative asset management firm that invests in innovative, growth-stage healthcare companies specializing in unique and transformative products, technologies, and services. • Madryn regularly invests in the private capital markets for growth-stage healthcare companies • We can invest across the capital structure and have a team with deep experience investing in both equity and debt instruments • Madryn has been an equity holder in SomaLogic since 2017, well before the 2021 SPAC transaction or the recently contemplated merger • Funds managed by Madryn currently own approximately 4.2% of SLGC’s common stock • Madryn’s funds do not have an activist mandate; in fact, this is the first time in Madryn’s history that it is publicly challenging a decision of one of its portfolio companies’ boards • As a fiduciary to our investors, we could not let the contemplated combination proceed without voicing our opposition • We greatly appreciate your time and consideration MADRYN ASSET MANAGEMENT 6

About SomaLogic (Nasdaq: SLGC) SomaLogic Powers Comprehensive Proteomic Insights Highest plex, highest data quality, most reliable proteome tool Key Stats 21% core revenue growth Differentiated technology Blue-Chip Customer Base 11K SOMAmers measuring 10K unique 185 SomaScan Services customers, 20% improvement in non-GAAP proteins from 55-microliter samples 16 authorized sites, relationships with operating expenses (over 2x more than alternatives) top biopharma companies Stock price has been challenged lately due to outsized SPAC Validated & Patented Proteomics Expertise expectations Scientific brilliance focused on 757 clinical publications and innovation, partnership, and power of protected by >600 patents proteomics $454 Million of Cash No Outstanding Debt 2023E Revenue Launched SomaScan Partnership expected Guidance 11K protein plex platform to launch in 2024 $82-$85mm ✓ illumina ___________________________________________________________ MADRYN ASSET MANAGEMENT 7 Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023.

SomaLogic Has A Proprietary Platform That No Other Company Can Replicate ✓ A proprietary platform (technology, database, bioinformatics) and a first-mover advantage ✓ 20 years of experience, and more than $500mm+ total investment in pre-SPAC technology ✓ More evolutionarily advanced position (enablement and applications) than any other proteomics company ✓ Market validated – many customers, established products, revenue and more of each assured ✓ The global leader in protein measurement, at 2.0x all competitors – 11,000 current ✓ The world’s largest clinical proteomics database ✓ The market leader in protein bioinformatics – 1bn+ protein measurements and 15mm+ clinical data points ✓ Core measurement reagent is nucleic acid, with significant technology trajectory options ✓ Valuable commercial Illumina partnership ___________________________________________________________ MADRYN ASSET MANAGEMENT 8 Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023.

About Standard BioTools (Nasdaq: LAB) Previously called Fluidigm, LAB has been a public company for many years • Mass cytometry technology underpinned by two platforms: flow cytometry and tissue imaging (spatial) o CyTOF XT Flow Cytometry: high-parameter single-cell protein analysis system and related assays o Hyperion Xti Imaging System: mid-plex spatial biology platform and related assays for imaging tissue and cells o Other genomics workflow assets • Company’s revenue trajectory has not been strong: o 2018: $113.0mm o 2019: $117.2mm o 2020: $138.1mm o 2021: $130.6mm o 2022: $97.9mm o 2023E: $100 – 105mm • New management team recently installed has been focused on cash preservation and evaluating transformative transactions o “Mission to Reinvigorate Growth through Optimization of Mass Cytometry and Microfluidics Platforms and Portfolio Expansion via Strategic Acquisitions” – LAB press release, 1/24/22 Messy Balance Sheet: $300mm+ in Senior Debt, Convertible Debt and Preferred Equity ___________________________________________________________ MADRYN ASSET MANAGEMENT 9 Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023.

The Proposed Merger Materially Undervalues SomaLogic The deal was executed haphazardly and drastically undervalues SomaLogic Implied Valuation Range Based on 2024E Revenue • SomaLogic’s equity, measured in several independent ways, is worth substantially more than the deal consideration, especially Comparable Companies: when considering the recently announced acquisition of OLK $1.82 $2.21 (1) • The deal price is based on historically low SomaLogic share prices $2.77 $4.58 Perella Fairness Comps • The OLK transaction created $132.9mm of equity value when SLGC SPAC – Disruptive $3.44 $5.37 considering the price appreciation and pro-forma FDSO (fully (2) Leading Platforms diluted shares outstanding) – why would SLGC give that away? (3) $2.37 $4.07 Centerview Fairness Comps • According to PitchBook, SomaLogic has raised a collective $1.26bn since its founding but the Board has recommended a Centerview DCF $2.90 $3.80 merger that values SomaLogic equity value near its cash balance, implying little to no enterprise value Perella DCF $2.59 $3.49 • The value of the consideration declined significantly prior to the announcement of the OLK acquisition, implying the market did not $0.00 $1.00 $2.00 $3.00 $4.00 $5.00 $6.00 like the transaction (4) (5) Unaffected Consideration Current Consideration Essentially, the SLGC Board is recommending shareholders vote to give away ~$125 - $800 million+ in (6) value to Standard ___________________________________________________________ Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023. SLGC share prices calculated using FDSO. (1) Perella Fairness Comps include NAUT, CTKB, OLK, QTRX, TWST, AKYA, MASS, SEER, QSI. Utilizes unaffected multiple for Olink (prior to acquisition announcement). (2) SLGC SPAC – Disruptive Leading Platforms include TXG, ABCL, ADPT, GH, NVTA, and TWST. Excludes CELL, as it was recently acquired. (3) Centerview Fairness Comps include NAUT, CTKB, OLK, QTRX, AKYA, MASS, SEER, QSI, NSTG. Utilizes unaffected multiple for Olink (prior to acquisition announcement). (4) Unaffected Consideration is calculated as of 10/16/2023. This calculation represents LAB closing price times the exchange ratio of 1.11. Importantly, this stock price is unaffected by the Olink announcement. MADRYN ASSET MANAGEMENT 10 (5) Current Consideration is calculated as of 12/15/2023. This calculation represents LAB closing price times the exchange ratio of 1.11. (6) Calculated as the difference between (1) SLGC FSDO x $1.82 and (2) SLGC FDSO times the high and low price per share shown in the “Implied Valuation Table Graphic.”

SomaLogic Is Severely Undervalued Compared to Its Only Peer Olink was valued at a ~$3.16 billion enterprise value in a transaction announced two weeks after the SLGC- (1) LAB deal • Olink, the only other high throughput proteomic market participant, is the template for SomaLogic’s potential value • October 17, just 13 days after the Proposed Merger was announced, Thermo Fisher Scientific Inc. (“Thermo Fisher” or “TMO”) announced it would acquire SomaLogic peer Olink for $3.16 billion, representing a 74% premium to the unaffected share price and a 14.6x EV/NTM revenue (1) multiple • In contrast, SomaLogic’s Board recommends consideration currently worth ~$417 million today, ~$37 million less than the Company’s 9/30/23 cash (2) balance and an implied EV that is -0.38x 2024 consensus revenue • Subsequent declines in LAB have pushed the value of the merger consideration to less than SLGC’s cash The Olink acquisition indicates that there is a disconnect between potential strategic partners’ valuation of SomaLogic and that of public markets ___________________________________________________________ Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023. (1) Per Capital IQ, accessed on 12/17/23. MADRYN ASSET MANAGEMENT 11 (2) Per FactSet, accessed on 12/17/23, based on SLGC basic shares outstanding.

The Value of the Consideration Declined Significantly in the Days Following the Proposed Merger Announcement Negative shareholder reaction to the deal initially impaired the value of Standard’s stock as currency for SomaLogic shareholders until the market saw the Olink acquisition 1-Day Stock Price Reaction (10/16/23 - 10/17/23) $3.50 SLGC 20.0% 10/17/23: TMO announces 10/04/23: SLGC and LAB LAB 18.3% acquisition of OLK announce merger Median $3.25 Perella Fairness Comps: 2.8% Centerview Fairness Comps: 1.2% SLGC SPAC - Distruptive Leading Platforms: 2.3% $3.00 $2.75 $2.50 $2.25 $2.00 Value Creation from Olink (2) Acquisition – Rerate $1.75 $132.9mm $1.50 10/3/23 10/16/23 10/29/23 11/11/23 11/24/23 12/7/23 12/15/23 (1) (1) Unaffected Consideration LAB Value at Announcement Effective Consideration ___________________________________________________________ Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023. (1) Unaffected Consideration is calculated as of 10/16/2023. This calculation represents LAB closing price times the exchange ratio of 1.11. Importantly, this date excludes the stock appreciation MADRYN ASSET MANAGEMENT 12 due to the Olink acquisition, which was announced on the following day. (2) Based on pro-forma Fully Diluted Shares Outstanding multiplied by the LAB stock price appreciation from 10/16/23 – 10/17/23. Value Per SLGC Share

Flawed Process Resulted in One-Sided Deal The proposed merger is the result of a deeply flawed and conflicted process ´ The transaction structure clearly benefits Casdin Capital through a non-traditional pro forma capital structure ´ Whether explicitly directed or not, SomaLogic’s Transaction Committee was clearly not independent and has incentives to structure a deal that benefits Casdin Capital ´ The merger process has unexplained gaps and shows that SomaLogic did not fulsomely evaluate all potential alternatives ´ The joint proxy statement (the Merger Proxy ) discloses that SomaLogic’s financial advisor has a clear financial incentive to render a fair opinion ´ The basis upon which the process was launched is deeply flawed – SomaLogic has plenty of cash runway, and transacting now only solidifies its historically low valuation MADRYN ASSET MANAGEMENT 13

Impact of the Merger on Governance Company-Specific Provision SomaLogic Combined Company ISS Governance QualityScore 9 10 Over 250,000 shares of Series B Preferred Stock issued and outstanding, held entirely by entities affiliated with SomaLogic and Multi-Class Stock Zero shares of preferred stock issued and outstanding Standard dual-director, Eli Casdin, Casdin Capital, and Viking Global (collectively, the “Holders of Series B-1 and B-2 Preferred Stock”) Holders of Series B-1 and B-2 Preferred Stock vote on an as- Preferred Stock with Unequal Voting converted basis with the common stock, expected to represent N/A Power approximately 20% of the voting power of the Combined Company on a pro forma basis Holders of Series B-1 and B-2 Preferred Stock have significant Preferred Stock Approval Rights and decision-making power at the Combined Company due to their N/A Consent Rights approval rights and consent rights (as further detailed on the next slide) Holders of Series B-1 and B-2 Preferred Stock each have the right Classified board of directors with three classes of directors, each to nominate and elect one member to the Combined Company’s Ability of Shareholders to Elect Directors serving a three-year term; holders of common stock may elect board, meaning shareholders may elect approximately only 71% of 100% of each class the Combined Company’s board, assuming a seven-member board Mr. Casdin appears to have significant power on the Combined Preferred Stock Representation on Company’s board; Mr. Casdin has financial, professional, and N/A Board personal connections with three of the six other members of the Combined Company’s board (see slide 30) If the merger is completed, SomaLogic shareholders will be subject to inferior corporate governance because of the deal structure put in place by Casdin ___________________________________________________________ MADRYN ASSET MANAGEMENT 14 Source: ISS, permission from ISS was neither sought nor provided, CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023.

Third-Party Analysts Criticized the Proposed Merger SLGC - LAB Merger Makes Strategic Sense; Valuation Is A Bit of A Surprise. “ (October 4, 2023) ” From a financial standpoint, we will admit we were somewhat surprised this morning by the roughly 30% premium on what is a severely depressed stock price, especially given the $475M on SLGC's balance sheet. While SLGC is no-doubt in a transition period, we continue to view “ them as a leader in the emerging high-plex proteomics space - so while we're not calling for a competing bid to emerge, the asset does seem as though it should have been able to fetch a higher price. (October 4, 2023) ” SomaLogic's current market cap trading below its $454M cash balance makes it less obvious that the all- “ stock merger will be approved by shareholders. (November 8, 2023) ” Based on LAB’s initial stock price reaction, SLGC holders get no premium at terms that now imply a ~$0 EV “ (October 5, 2023) ” Investors clearly would prefer a higher valuation. (October 4, 2023) “ ” [W]e believe the shares (trading below the value of SLGC's cash balance) currently do not reflect the company's long- “ term growth potential. (August 14, 2023) ” ___________________________________________________ MADRYN ASSET MANAGEMENT 15 Source: Equity research reports.

There Is a Superior Path Forward We believe there are alternative paths that could deliver far superior value to the proposed merger ✓SLGC’s continued operational re-organization, commercial execution, and ongoing R&D efforts can create value for shareholders – permanent management should be installed ✓The distributed kit product launch can be transformative for the Company from a revenue and growth perspective ✓The mid-to-high-plex proteomics market is in its infancy and SLGC will continue to benefit from that tailwind ✓There is no operational downside to SLGC if it does not consummate the merger; SLGC is a scarce asset and can likely fetch a strong valuation in the future MADRYN ASSET MANAGEMENT 16

II. The Proposed Merger Materially Undervalues SLGC

The Proposed Merger Significantly Undervalues SomaLogic • LAB’s shares traded down 39% until Olink’s acquisition was announced on October 17th, 2023 • The current value of consideration reflects more favorable views of SomaLogic’s business after The value of the consideration declined OLK was acquired and that is not priced into the deal significantly prior to the announcement of the 1• The real unaffected consideration is the unaffected LAB stock price (as of October 16th, 2023, Olink acquisition and directly prior to Olink’s announced acquisition) multiplied by the proposed exchange ratio of 1.11 • The transaction values SomaLogic at a trough in its valuation, while the Company faces no The deal price is based on historically low pressure to transact SomaLogic share prices 2 • The growth LST/Dx segment has traded down substantially over the last two years • SomaLogic’s business has been improving lately and there are several important catalysts that The value is inadequate based on both an have yet to occur objective valuation analysis and 3• An objective valuation framework utilizing the latest share prices shows that the consideration management’s own projections is inadequate • The announcement of Olink’s acquisition occurred just 13 days after the announcement of the The deal was announced prior to the Proposed Merger and suggests SomaLogic is worth more than the consideration being paid acquisition of SomaLogic’s key competitor, 4• Standalone SomaLogic has an opportunity to achieve outsized outcomes like the Olink Olink, for $3.16 billion by Thermo Fisher acquisition ___________________________________________________________ MADRYN ASSET MANAGEMENT 18 Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023.

1 Negative Market Reaction to Deal Announcement Reversed When Olink Acquisition Proved SomaLogic's Potential Value In contrast to a typical merger, where changes in the acquirer's shares pull the target along, this is an instance of a change in the value of the target pushing up the value of the acquirer 1-Day Stock Price Reaction (10/16/23 - 10/17/23) $3.50 SLGC 20.0% 10/17/23: TMO announces 10/04/23: SLGC and LAB LAB 18.3% acquisition of OLK announce merger Median $3.25 Perella Fairness Comps: 2.8% Centerview Fairness Comps: 1.2% SLGC SPAC - Distruptive Leading Platforms: 2.3% $3.00 $2.75 $2.50 $2.25 $2.00 Value Creation from Olink (2) Acquisition – Rerate $1.75 $132.9mm $1.50 10/3/23 10/16/23 10/29/23 11/11/23 11/24/23 12/7/23 12/15/23 (1) (1) LAB Value at Announcement EUn ffectiv affect e ed C Cono snsiderati ideration on ___________________________________________________________ Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023. (1) Unaffected Consideration is calculated as of 10/16/2023. This calculation represents LAB closing price times the exchange ratio of 1.11. Importantly, this date excludes the stock appreciation MADRYN ASSET MANAGEMENT 19 due to the Olink acquisition, which was announced on the following day. (2) Based on pro-forma Fully Diluted Shares Outstanding multiplied by the LAB stock price appreciation from 10/16/23 – 10/17/23. Value Per SLGC Share

1 The Proposed Merger Consideration Is Well Below Analyst Price Targets and Reflects a Minuscule Premium • The transaction values SomaLogic at a trough in its valuation even though the Company faces no pressure to transact • SomaLogic’s public market valuation at the time of announcement was near all-time lows and divorced from SomaLogic’s potential, yet the Board chose to use it as a basis for the premium calculation • The Proposed Merger offers SLGC shareholders insufficient value in an unnecessary transaction that is unresponsive to maximizing SLGC shareholder return (1) (2) SLGC Mean Analyst Price Targets SLGC Premium Analysis Post-Deal Unaffected Mean SLGC Analyst Consideration: $1.82 Price Target: $5.00 Cowen & Company $7.00 8/15/2023 Stifel Nicolaus $7.00 10/3/2023 Jefferies $3.50 8/15/2023 Canaccord Genuity $2.50 10/3/2023 ___________________________________________________________ Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023. (1) Unaffected Consideration is calculated as of 10/16/2023. This calculation represents LAB closing price times the exchange ratio of 1.11. Importantly, this date excludes the stock appreciation MADRYN ASSET MANAGEMENT 20 due to the Olink acquisition, which was announced on the following day. (2) Premiums determined comparing SLGC unaffected 10/3/21 stock price, except for the 52-week calculation and the SPAC price calculation.

2 Deal Price Is Materially Lower Than Recent Trading Prices SLGC shares since start of trading confirms deal was struck near all-time lows $15 $13 $11 $9 $7 October 3, 2023 $5 $3 $1 Deal value as of December 15, 2023 Sep 21 Dec 23 • The current 1.11x exchange ratio is based on an artificially deflated SLGC share price (does not reflect pending catalysts) • This share price is unnecessarily burdened due to SLGC’s lack of full-time management team and recent lack of focus • The current share price does not accurately incorporate the anticipated value creation from the upcoming launch of the co-branded product with ILMN ___________________________________________________________ MADRYN ASSET MANAGEMENT 21 Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023.

2 The Growth LST/Dx Segment Has Traded Down Substantially Over the Last Few Years But SomaLogic Can Weather the Storm Growth Life Science Tools/Diagnostics Valuations Have • Growth life science tools companies are trading at Disproportionately Suffered in the Current Environment substantial discounts to 5-year averages; consequently, these growth companies should not transact unless EV / NTM EBITDA EV / NTM Revenue absolutely necessary • Per SomaLogic’s management team’s own projections, 19.4x 13.0x SomaLogic is uniquely positioned to weather the cycle 13.1x Median NTM 11.1x Multiple with a clean balance sheet and runway to cashflow 5yr Median breakeven 4.9x 13.3x 19.7x 14.3x • Part of the reason that SomaLogic engaged in a SPAC (2) (3) (1) S&P 500 Large Cap LST/Dx SMid Cap LST/Dx Growth LST/Dx transaction was to SomaLogic Has Years of Runway to Create Value and to “give companies like a SomaLogic an enormous Allow Trading Multiples to Recover to Historical Averages amount of capital and great board sponsorship and expertise so that they can ride through these $559 $600 (4) SLGC Forecasted Cash Balance moments of dislocation and come out the other side” $500 ($ in million) $413 $402 -Eli Casdin, April 1, 2021 $400 $307 $296 $300 $235 $231 • The ability for standalone SomaLogic to weather the $191 $192 $172 $173 $200 environment remains true today $100 $0 ___________________________________________________________ 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023. (1) LST/Dx Large Cap includes A, AVTR, BRKR, DHR, PKI, QGEN, TECH, TMO, WAT, ILMN, BIO, BIM, and MTD. (2) LST/Dx SMidCap includes MRVI, ABCM, NTRA, DIA-IT, NVTA, QDEL, NEO, ADPT, CDNA, VCYT, and MYGN. Excludes EBITDA multiples over 40x that are typically not meaningful. (3) Growth LST/Dx includes TXG, TWST, BLI, GH, RPID, MXCT, ISO, AKYA, OLK, OMIC, EXAS, NSTG and SEER. MADRYN ASSET MANAGEMENT 22 (4) Per SomaLogic management projections in merger proxy. Forecasted cash balance represents 2022 year end actual cash and cash equivalents plus short-term investments. Subsequent years are projected by incorporating SomaLogic management’s unlevered FCF projections, per merger proxy.

3 Management’s Projections Indicate Accelerated Growth Revenue ($ in millions) $500 • SLGC management expresses continued confidence in its $404 $368 $400 $331 core business and its future prospects $295 $261 $300 $228 $198 $170 $200 $143 o “I would say most of the time we're seeing fantastic $106 $85 $100 growth in both customer segments, but we're really $0 starting to accelerate and penetrate more deeply in the 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 biopharma.” – Adam Taich, interim CEO, Nov. 8, 2023 Unlevered FCF ($ in millions) o “We are reiterating our 2023 revenue guidance of $80 $200 $146 million to $84 million. We continue to see 2023 as a $150 $106 building year for the organization while our teams $100 $72 worked diligently on the many growth drivers ahead.” $43 $50 $19 $1 2023 2024 2025 2026 2027 – Eliot M. Lurier, former interim CFO, Aug. 15, 2023 $- 2028 2029 2030 2031 2032 2033 $(19) $(50) $(40) • SomaLogic’s projections disclosed in the Merger Proxy reflect $(65) $(100) its expectations that SomaLogic’s growth will continue $(106) $(150) $(138) unabated and its financial profile will improve $(200) Forecasted Year End Cash Balance ($ in millions) • We believe SomaLogic has the runway to achieve this plan $559 $600 $500 $413 $402 $400 $307 $296 $300 $235 $231 $191 $192 $172 $173 $200 $100 $0 ___________________________________________________________ 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Source: SomaLogic management projections per Merger Proxy. CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023. MADRYN ASSET MANAGEMENT 23 Note: Forecasted cash balance represents 2022 year end actual cash and cash equivalents plus short-term investments. Subsequent years are projected by incorporating SomaLogic management’s unlevered FCF projections, per Merger Proxy.

3 Management’s Own Projections Suggest SomaLogic Is Worth More Than the Consideration Perella Weinberg Partners LP (“PWP”) DCF Valuation • On a standalone basis, we believe SomaLogic has enough runway to create substantial value for shareholders $1.82 $2.21 (1) Unaffected Consideration (2) • Management’s own projections show SomaLogic reaching Current Consideration $404mm in revenue in 2033 $2.59 $3.49 • At no point is SomaLogic projected to have a negative cash balance or require additional financing $0.00 $1.00 $2.00 $3.00 $4.00 $5.00 $6.00 Revenue ($ in millions) Unlevered FCF ($ in millions) $500 $200 $146 $150 $404 $400 $106 $368 $100 $331 $72 $295 $43 $50 $300 $261 $19 $1 2023 2024 2025 2026 2027 $228 $- $198 2028 2029 2030 2031 2032 2033 $200 $170 $(19) $(50) $143 $(40) $106 $(65) $85 $(100) $100 $(106) $(150) $(138) $0 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 $(200) ___________________________________________________________ Source: SomaLogic management projections per Merger Proxy. SomaLogic filings. (1) Unaffected Consideration is calculated as of 10/16/2023. This calculation represents LAB closing price times the exchange ratio of 1.11. Importantly, this date excludes the stock appreciation due to the Olink acquisition, which was announced on the following day. MADRYN ASSET MANAGEMENT 24 (2) Current Consideration is calculated as of 12/15/2023. This calculation represents LAB closing price times the exchange ratio of 1.11.

3 We Believe SomaLogic Deserves a Much Higher Valuation Implied Valuation Range Based on 2024E Revenue • All objective valuation analyses point to an unfair deal: Comparable Companies: th th $1.82 $2.21 o When considering the 25 – 75 percentile of each fairness opinion’s selected comparable companies analysis (1) $2.77 $4.58 PWP Fairness Comps at today’s trading prices, the consideration is clearly too low SLGC SPAC – Disruptive $3.44 $5.37 (2) Leading Platforms th th o When considering 25 – 75 percentile of the group of “Disruptive Leading Platforms” that the Company utilized (3) $2.37 $4.07 Centerview Fairness Comps in its initial SPAC announcement presentation, the consideration is clearly too low Centerview DCF $2.90 $3.80 o When considering both discounted cash flow analyses Perella DCF conducted by PWP and Centerview, the consideration is $2.59 $3.49 clearly too low $0.00 $1.00 $2.00 $3.00 $4.00 $5.00 $6.00 • Further, the current consideration is inflated by the re-rate in (4) (5) Unaffected Consideration Current Consideration both SLGC and LAB share prices due to the OLK announced acquisition EV/2024E Revenue Multiples 25th Percentile Median 75th Percentile o When referencing the last unaffected price of LAB shares, (1) the deal is substantially unfair Perella Fairness Comps: 1.80x 4.41x 5.98x (2) (2) SLGC SPAC - Distruptive Leading Platforms: 3.36x 5.63x 7.82x (3) Centerview Comps 0.88x 2.07x 4.82x ___________________________________________________________ Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023. SLGC share prices calculated using FDSO. (1) Perella Fairness Comps include NAUT, CTKB, OLK, QTRX, TWST, AKYA, MASS, SEER, QSI. Utilizes unaffected multiple for Olink (prior to acquisition announcement). (2) SLGC SPAC – Disruptive Leading Platforms include TXG, ABCL, ADPT, GH, NVTA, and TWST. Excludes CELL, as it was recently acquired. (3) Centerview Fairness Comps include NAUT, CTKB, OLK, QTRX, AKYA, MASS, SEER, QSI, NSTG. Utilizes unaffected multiple for Olink (prior to acquisition announcement). MADRYN ASSET MANAGEMENT 25 (4) Unaffected Consideration is calculated as of 10/16/2023. This calculation represents LAB closing price times the exchange ratio of 1.11. Importantly, this stock price is unaffected by the Olink announcement. (5) Current Consideration is calculated as of 12/15/2023. This calculation represents LAB closing price times the exchange ratio of 1.11.

4 The Olink Transaction Proves There Is Substantial Upside for SomaLogic • SomaLogic and Olink are the only high-plex proteomic players with (1) Comparison of SomaLogic and Olink scale, and many analysts and investors believe SomaLogic’s technology is superior: The long promised power of proteomics is quickly becoming a 2022A Revenue $97.7 million $139.7 million “ commercial and clinical reality and in our view, SomaLogic is the leading platform in the field. 2023E Revenue $83.8 million $192.0 million No permanent ” Stable Management? Steady –Eli Casdin, SomaLogic Press Release, March 29, 2021 CEO or CFO Stable Board? Recent Board Departures Steady • The Proposed Merger severely undervalues SomaLogic when compared to Olink – its only true peer Enterprise Value ($19 million) $1,680 million o Olink was valued at $3.1 billion in a transaction announced on # of Proteins 11,000 5,400 10/17/23, at a 74% premium to the 10/16/23 OLK closing Measured stock price o In contrast, SomaLogic is being acquired for ~$417mm, based on current value (a/o Dec. 15, 2023) of the consideration (2) which now also reflects the bump from the OLK acquisition The Board has an obligation to consider if the Olink acquisition means SomaLogic is undervalued and should remain standalone to accrue additional value for SomaLogic shareholders ___________________________________________________________ Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023. MADRYN ASSET MANAGEMENT 26 (1) Enterprise Values per FactSet as of 10/03/2023. Represents pre-announcement / unaffected SomaLogic valuation. (2) Per FactSet, accessed on 12/17/23, based on SLGC basic shares outstanding.

III. The Proposed Merger is the Result of a Deeply Flawed and Conflicted Process

The Proposed Merger is the Result of a Deeply Flawed and Conflicted Process • Casdin Capital retains its valuable change-of-control put right associated with the Series B Preferred Stock The transaction structure clearly benefits • Casdin Capital retains its outsized governance and voting rights despite LAB’s pro forma “minority” ownership Casdin Capital through a non-traditional pro- 1 • Casdin Capital supports its LAB position by infusing $450mm of cash along with SomaLogic’s unique forma capital structure technology into what may become a challenged position Whether explicitly directed or not, • Mr. Casdin’s recusal from the SomaLogic Transaction Committee doesn’t solve the issue of deep SomaLogic’s transaction committee was interconnectedness with his fellow board members clearly not independent and has incentives to • The SomaLogic Transaction Committee, which was composed of new board members after the abrupt 2 structure a deal that benefits Mr. Casdin and departure of three previous directors, had little skin-in-the-game in SomaLogic; on the other hand, Mr. Casdin’s influence matters more in other situations for them Casdin Capital The merger process has unexplained gaps • The Merger Proxy discloses several sets of discussions with LAB that went nowhere and shows that SomaLogic did not fulsomely • Even if the fundamentals of the deal made more sense in summer 2023, SomaLogic appears to have 3 evaluate all potential alternatives not run a legitimate and fair process The Merger Proxy explicitly states that SomaLogic’s financial advisor expects that it • The Merger Proxy explicitly states that PWP is attempting to win future business from a company may be paid by a company controlled by controlled by Mr. Casdin; that is deeply concerning and calls into question PWP’s independence 4 1 Casdin The basis upon which the process was • Based on management’s forecasts, SLGC has plenty of runway to create value for shareholders as a launched is deeply flawed – SomaLogic has standalone company • The growth life science tools market is trading at all-time lows and companies should not transact 5 years of runway and transacting now only unless necessary to extend runway solidifies its historically low valuation ___________________________________________________________ MADRYN ASSET MANAGEMENT 28 Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023. (1) SLGC-LAB Merger Proxy, page 121.

1 The Transaction Structure Disproportionately Benefits Casdin Capital Casdin Capital retains the valuable Series B Put Right, exercisable upon a future change-in-control • It is incredibly concerning that Casdin Capital and Viking Global What is the Series B Preferred Stock and Associated Put Right? can force the Company to repay the value of their investment in cash in a liquidation or change of control transaction (e.g., • The Series B Preferred Stock is the financial instrument through which Casdin merger, sale, or downside outcome) Capital invested in LAB • Among other things, the Series B Preferred Stock contains dividend rights, • SomaLogic shareholders had no involvement with LAB’s liquidation rights, conversion and redemption rights, and specialized voting and decision to issue expensive, debt-like equity securities and consent rights should not be burdened by them going forward • Importantly, the Series B Preferred Stock ranks senior to common equity in any liquidation or change-of-control scenarios • When considering LAB’s senior debt and convertible debt, • Reading the fine print, the Series B Preferred Stock also contains debt-like SLGC shareholders are junior to approximately $314mm of downside protections: legacy LAB securities in a change of control despite having a • Liquidation Rights: A liquidation preference equal to the greater of the following, clean balance sheet today payable in cash, (i) the Liquidation Preference (~$250mm) and (ii) the as converted value of the preferred (i.e., ~75mm shares worth of value) • A review of recent life sciences mergers revealed that no combined company had preferred stock• Change of Control Rights: If the Company undergoes a change of control (e.g., a future merger or acquisition), then the Series B Preferred Stockholders get the greater of following, payable in cash, (i) the liquidation preference (~$250mm) or • It is noteworthy that SomaLogic's fairness opinion did not (ii) the amount of cash and/or other consideration that such holder would be include a Selected Comparable Transactions Analysis entitled to receive on an as converted basis (i.e., ~75mm shares worth of value) The SLGC Board is recommending shareholders accept a transaction in which they would be junior to a substantial amount of LAB’s equity – including Casdin Capital’s preferred equity ___________________________________________________________ MADRYN ASSET MANAGEMENT 29 Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023.

1 Standard and Casdin Will Maintain Outsized Control of the Combined Entity The Series B Preferred Stock contains outsized voting/consent rights that leave SomaLogic stakeholders beholden to Casdin Capital What special voting/consent rights does the Series B Preferred • Typically, pro forma governance in a merger mirrors the Stock have? ownership split negotiated in the deal – that is clearly not • A majority vote of the Series B Preferred Stock or written approval is required for taking the the case here following actions: o (i) issuing new securities with rights ranking senior to or on parity with the Series B • The pro forma board will be composed of professionals with Preferred Stock known ties to Mr. Casdin: o (ii) the declaration or payment of any dividend or distribution o (iii) the purchase, redemption, or other acquisition of any capital stock of the Company ranking junior to the Series B Preferred Stock Combined Company Board of Directors: o (iv) any amendment to the rights, powers, preferences, privileges, or voting powers of the Series B Preferred Stock o (v) any amendment to the charter or bylaws that would have an adverse effect on the rights, preferences, privileges, or voting power of the Series B Preferred Stock • Additionally, Casdin, through the Series B Preferred Stock class, has the right to nominate members to the board of directors at all times • Finally, Casdin, as a designee of the Series B Preferred Stock, has specific consent rights over, Michael Egholm Eli Casdin Troy Cox Kathy Hibbs among other things: o Any increase in the number of directors beyond seven o Hiring, promotion, demotion, or termination of the CEO o Any bankruptcy filing o Any change in the business of combined company Frank Whitney Fenel Eloi Tom Carey o Any material acquisitions o Any material sale of assets Connected to Mr. Casdin ___________________________________________________________ MADRYN ASSET MANAGEMENT 30 Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023.

1 Approval and Consent Rights of Holders of Series B-1 and B-2 Preferred Stock Holders of Series B-1 and B-2 Preferred Stock maintain substantial If the Proposed Merger is approval and consent rights in the Combined Company completed, the rights of SomaLogic shareholders will be inferior to those of Holders of • Holders of Series B-1 and B-2 Preferred Stock have approval rights, meaning that approval of at least 60% of the outstanding Series B Preferred Stock is required to: Series B-1 and B-2 Preferred Stock, namely Mr. Casdin o amend the Charter to create any new series of securities with rights ranking senior to/on parity with the Series B-1 and B-2 Preferred Stock o declare/pay any dividend/distribution o purchase, redeem, or acquire common stock or other capital stock ranking junior to the Series B-1 and B-2 Preferred Stock Holders of Series B-1 and B-2 o amend the rights/voting powers of the Series B-1 Preferred Stock or the Series B-2 Preferred Stock Preferred Stock “may be able to o amend the Charter or Bylaws in any way that would have an adverse effect on the Series B-1 Preferred determine or significantly Stock or the Series B-2 Preferred Stock influence matters requiring • Director designees of Holders of Series B-1 and B-2 Preferred Stock have consent rights over, among other shareholder approval. The things: interests of significant o any increase in the number of directors beyond seven shareholders may not always coincide with the interests of the o hiring, promoting, demoting, or terminating the Chief Executive Officer Combined Company or the o entering into or modifying any Related Person transactions interests of other shareholders.” o any change in the principal business or entry into any new line of business – DEFM14A, filed by SomaLogic with o certain acquisitions (including by merger) and dispositions the SEC on December 1, 2023 ___________________________________________________________ MADRYN ASSET MANAGEMENT 31 Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023.

1 Casdin Capital’s LAB Position Benefits Greatly from the Proposed Merger The deal greatly benefits LAB and Casdin Capital by de-risking LAB’s cash and runway at the expense of SomaLogic shareholders Pay Out Structure in Future Change of Control • In addition to retaining the Series B Put Right and other valuable rights, Casdin Capital also benefits by 1.) $9.2mm of Senior Debt buoying LAB’s balance sheet with substantial cash and SomaLogic assets: 2.) $55mm of Convertible Debt o LAB has $64.2mm in debt maturing by 12/31/2024 3.) $250mm+ of Series B Preferred Stock o LAB is expected to burn $52mm over that period on an unlevered basis (excluding debt (1) repayment) according to LAB management 4.) SLGC Shareholders and LAB Common Holders o LAB would likely need to finance in the next 12 months to fund its operations and satisfy Cash and Cash Equivalents Debt and Debt-Like Securities As of 09/30/2023 its debt obligations o If LAB was forced to engage the public capital $128.9 million $314.2 million markets for a financing, the deal terms may prove onerous due to its messy balance sheet $453.8 million $0.0 million o The SLGC deal solves LAB’s impending cash crush on favorable terms Pro Forma Combined Entity $582.7 million $317.0 million The deal seems more like a bailout for LAB than an enhanced value opportunity for SLGC shareholders ___________________________________________________________ MADRYN ASSET MANAGEMENT 32 Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023. (1) Calculated as 25%*2023 unlevered FCF + 2024 unlevered FCF.

2 March 2023 Board Changes Lead to Questions Regarding Mr. Casdin’s Influence One month before discussions with LAB resumed, the SLGC Board and Transaction Committee underwent significant changes that appear to be influenced by Mr. Casdin SLGC Board Prior to March 2023: SLGC Board Post-March 2023 Shake Up: *Transaction Committee Eli Casdin* Eli Casdin Robert Barchi Troy Cox* Tycho Peterson* Robert Barchi Troy Cox Roy Smythe Charles M. Lillis Richard Post Jason Ryan* Stephen Quake Richard Post Tom Carey* Connected to Mr. Casdin Anne Margulies Kevin Conroy Ted Meisel Anne Margulies Kathy Hibbs ___________________________________________________________ MADRYN ASSET MANAGEMENT 33 Note: Names with a strikethrough were removed prior to end of March 2023.

2 Mr. Casdin’s Connections to the Transaction Committee Void His “Recusal” A review of Mr. Casdin’s relationships with SomaLogic Board members reveals troubling conflicts of interest Eli Casdin SomaLogic Director • Founder of Perspective Group, where Casdin • Former CEO at Foundation Medicine, Capital is a client Series B financing led by Casdin Capital • Director at Exact Sciences, where Casdin • Current Director and former board chair Troy Cox at LetsGetChecked, where Casdin Capital is an investor Tom Carey SomaLogic Director Capital is an investor SomaLogic Director • Current Director at Zymeworks, where Casdin Capital was listed as a shareholder in 2020 SLGC Transaction Committee Combined Company Board Member • CFO at Magenta Therapeutics when Casdin Capital led Series C financing • Served on the board of Sema4 alongside Casdin Capital • Adaptive CEO Chad Robins sits on the • Former CFO at Foundation Medicine, where Casdin Capital was an investor board of CM Life Sciences III, a SPAC • Director at Singular Genomics, where Casdin sponsored by Casdin Capital Capital was an investor • Executive Chair at GeneDx, where Casdin Capital is an investor • Former Director at ArcherDx, where Casdin Capital was an investor Jason Ryan Tycho Peterson SomaLogic Chair SomaLogic Director ___________________________________________________________ MADRYN ASSET MANAGEMENT 34 Source: Company filings and Press Releases.

3 The Merger Process Has Unexplained Gaps With Lack of Disclosure SLGC Transaction Meetings are held in SLGC signals to LAB it Committee, after SomaLogic Informal discussions to “Counterparty B” Boulder, CO and San will not accept revised hearing that Casdin Completes SPAC further explore the signals interest in a Diego, CA, respectively, exchange ratio; unclear Capital will not remove Transaction with strategic rationale of a minority investment to facilitate diligence what the dialogue was the Put Right, suddenly CM Life Sciences II, potential combination in SLGC decides the onerous between SLGC and LAB on Put Right Inc. term is acceptable Dr. Smythe resigns; two SLGC counter proposal Casdin independent directors is delivered to LAB; Put Legal Representatives Mr. Casdin is recused Capital retire; Mr. Taich is Right is explicitly of Casdin Capital are from SLGC Transaction Leads appointed interim CEO; removed for Series B notified that SLGC Committee $250mm four new directors are Preferred Stockholders wants Put Right investment appointed to the Board in the combined entity removed in LAB 8/8/22 and May/Early Undisclosed time 9/1/21 4/2022 10/3/22 3/28/23 June 2023 after June 16 7/27/23 8/12/23 8/18/23 9/25/23 10/1/23 2/14/22 6/2/22 11/2022 4/28/23 6/16/23 7/6/23 8/2/23 8/17/23 August and 9/27/23 10/4/23 September SLGC receives June 16 Discussions are terminated Negotiation on SLGC and LAB enter Proposal from LAB; Mr. “Counterparty G” without any specific exchange ratio; into NDA to facilitate Casdin is recused from signals interest in a valuation or other terms SLGC makes clear Proposed discussions; no LAB transaction minority investment being proposed and no Put Right not proposals result committee but is still a in SLGC term-sheets acceptable Merger Is part of SLGC Transaction Committee Announced Legal reps of Casdin Dr. Egholm (CEO LAB) and SLGC Transaction Capital and Viking Dr. Smythe (CEO SLGC) Egholm and Mr. Taich Committee LAB proposes communicate that both hold an intro call to discuss hold call to discuss instructs PWP to counter proposal; parties are unwilling to interest in exploring a interest in pursuing a remove Put Right contact 16 other re-inserts Put Right combination of LAB and transaction parties about a deal SLGC ___________________________________________________________ MADRYN ASSET MANAGEMENT 35 Source: SLGC-LAB Merger Proxy.

3 Key Questions Regarding the Process Why wasn’t Mr. Casdin recused earlier from the SomaLogic Transaction Committee? There was substantive back and 1 forth between the companies while he remained on both transaction committees Why did initial discussions with LAB terminate? Why did certain board members and the former CEO Roy Smythe resign 2 in March 2023 (just before discussions with LAB resumed in April 2023)? Did it have anything to do with the LAB deal? Was the Board aware that the four “independent” board members appointed in March 2023 had prior connections to 3 Mr. Casdin? 4 Was the Board aware that every member of the SomaLogic Transaction Committee had prior connections to Mr. Casdin? Why weren’t the minority investment opportunities advanced? If those investments could have resulted in a strategic 5 investor supporting SLGC’s commercialization efforts, that could be value-maximizing for SLGC shareholders 6 How did the SLGC Transaction Committee suddenly get comfortable with Casdin Capital’s retention of the Put Right? Why are each of the SomaLogic designees for the board of directors of the combined company individuals with identified 7 connections to Mr. Casdin? MADRYN ASSET MANAGEMENT 36

3 SLGC's Former CEO Opposed a Merger With LAB Twice “ The first time the company was asked to consider a merger with Standard BioTools … [t]he strong consensus was the Standard BioTools technology and products were not additive or synergistic and SomaLogic’s balance sheet did not require any additional capital. The M&A committee of the board asked the management team to ‘kill’ the deal … [t]here was subsequent contention between a board member and the management group / CEO for not supporting the proposal. Several months later, the management team was again asked to evaluate the deal, after looking at other opportunities. The recommendation from management was unchanged… I did not believe this deal provided for commercial lift, and there was adequate capital to continue the current plan of commercial team growth and product diversification - with significant market interest in the standalone company. In both of the two years prior to my departure, the company doubled its customer base, and it is my understanding this trend has continued. ” -Roy Smythe, former SomaLogic CEO MADRYN ASSET MANAGEMENT 37

3 Additional Questions About SomaLogic’s Process SLGC’s process was characterized by an abbreviated diligence period and what appears to be cursory efforts to evaluate other transaction options • SomaLogic was granted access to LAB’s data room on September th 20 • How was SomaLogic able to fulsomely evaluate LAB o The merger agreement between SomaLogic and Standard was as a merger counterparty within what appears to be th executed October 4 , just two weeks later an extremely narrow diligence window? o Consider this timeline in light of Thermo Fisher’s recent acquisition of proteomics player Olink, where nine weeks elapsed between data room • How is it possible that just one transaction access and merger agreement execution counterparty out of 16 progressed to the execution • PWP reached out to 16 potential transaction counterparties on of an NDA with SLGC when several parties indicated behalf of SomaLogic; however: interest in a minority investment? o Just one of the counterparties contacted by PWP entered into a confidential disclosure agreement in connection with this outreach o Compare these efforts to those in the Olink transaction. While only seven strategic bidders were contacted, six parties entered into an NDA, five parties conducted management info sessions, and three parties submitted IOIs SomaLogic shareholders deserve more transparency into the nature and quality of the diligence process and PWP’s outreach efforts ___________________________________________________________ MADRYN ASSET MANAGEMENT 38 Source: SLGC-LAB Merger Proxy.

4 We Question the Independence of SLGC’s Financial Advisor The Merger Proxy discloses that SLGC’s advisor was conflicted • The Merger Proxy says on page 121 that SomaLogic’s financial advisor expects that it may be compensated by Casdin Capital, the conflicted shareholder with positions in both SLGC and LAB Shareholders should be concerned that the Board is using a financial advisor that expects to be paid by a separate company controlled by Casdin Capital ___________________________________________________________ MADRYN ASSET MANAGEMENT 39 Source: SLGC-LAB Merger Proxy.

5 SomaLogic Does Not Need to Transact SomaLogic has significant growth potential as a standalone entity and does not need to transact at this time • The basis upon which the SomaLogic strategic process was launched was deeply flawed (a purported review of financing sources for a company with sufficient cash) • SLGC has plenty of runway • Growth LST/Dx companies are trading at all-time lows; transacting now locks in historically low valuation for SLGC shareholders Growth Life Science Tools/Diagnostics Valuations Have (1) Disproportionately Suffered in the Current Environment SLGC’s Forecasted Cash Balance ($ in millions) $600 $559 EV / NTM EBITDA EV / NTM Revenue $500 $413 19.4x $402 $400 13.0x 13.1x $307 11.1x $296 $300 $235 $231 $191 $192 $173 $200 $172 4.9x 13.3x 19.7x 14.3x (2) (3) (1) (3) (4) (2) S&P 500 Large Cap LST/Dx SMid Cap LST/Dx Growth LST/Dx $100 Median NTM Multiple $0 5yr Median 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 ___________________________________________________________ Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023. (1) Per SomaLogic management projections in merger proxy. Forecasted cash balance represents 2022 year end actual cash and cash equivalents plus short-term investments. Subsequent years are projected by incorporating SomaLogic management’s unlevered FCF projections, per merger proxy. (2) LST/Dx Large Cap includes A, AVTR, BRKR, DHR, PKI, QGEN, TECH, TMO, WAT, ILMN, BIO, BIM, and MTD. MADRYN ASSET MANAGEMENT 40 (3) LST/Dx SMidCap includes MRVI, ABCM, NTRA, DIA-IT, NVTA, QDEL, NEO, ADPT, CDNA, VCYT, and MYGN. Excludes EBITDA multiples over 40x that are typically not meaningful. (4) Growth LST/Dx includes TXG, TWST, BLI, GH, RPID, MXCT, ISO, AKYA, OLK, OMIC, EXAS, NSTG and SEER.

What SLGC Shareholders Should be Asking 1 The Preferred equity is effectively debt until it is in-the-money. Why would retaining this structured capital be acceptable to SLGC shareholders? Why did the SomaLogic Board ignore the clear conflicts of interest between Mr. Casdin and the rest of the Board, including each member of the transaction 2 committee? Will the Merger Proxy be updated to reflect these conflicts? After the Proposed Merger, SomaLogic shareholders will hold 57% of the combined company but only have the right to designate three directors to a seven- 3 director board that includes two directors appointed by Casdin Capital and Viking. Why does the merger agreement give Standard the right to appoint a number of directors that is disproportionate to their stake in the new entity? The Merger Proxy clearly explains that the SomaLogic Transaction Committee initially was not comfortable burdening the pro forma combined company with the 4 Series B Put Right but suddenly became comfortable – what caused this change? The proxy does not contain adequate disclosure around whether minority investment transactions were fulsomely considered by the SomaLogic Transaction 5 Committee. Did the SomaLogic Transaction Committee further explore those minority investment transactions or consider expanding the universe of contacted parties who may be interested in such a transaction? How did the SomaLogic Transaction Committee gain comfort around the outsized voting and consent rights afforded to Series B Preferred Stockholders (i.e., 6 consent rights on the incurrence of indebtedness, changes to the size of the board, appointment or removal of the CEO, etc.)? SomaLogic has significant growth potential with a strong, cash-rich balance sheet that provides several years of runway. Given the current headwinds facing all 7 growth-stage life science tools companies, why should SomaLogic transact in the current environment? Why did initial discussions with LAB terminate? Why did certain board members and the former CEO Roy Smythe resign in March 2023 (just before discussions 8 with LAB resumed in April 2023)? Quotes from former CEO indicate that there was pressure to do a deal and that the old conformation of the board did not support the transaction. MADRYN ASSET MANAGEMENT 41

IV. SLGC Has Far Superior Prospects, Including as a Standalone Company

SLGC Has Far Superior Prospects, Including as a Standalone Company • According to the Merger Proxy, SLGC’s cost-savings / operational re-organization is going well and will SLGC’s continued operational re- generate ~$27mm in run-rate OpEx savings by 2026 organization, commercial execution, and • SLGC continues to make commercial progress in a tough macroeconomic environment ahead of its ongoing R&D efforts can likely create value distributed kit launch 1 for shareholders – permanent management • SLGC’s pipeline continues to mature positively should be installed • Why didn’t the Board take the search for a new management team seriously? • Launching the co-branded kit with ILMN will give SLGC the commercial heft it needs to properly serve We believe that the distributed kit product the market for proteomics launch can be transformative for the • SLGC continues to state that the decentralized kit, partnered with ILMN, is advancing to a pilot early 2 next year Company from a revenue and growth • SLGC is advancing other avenues to create decentralized kits as a hedge to the ILMN partnership and perspective future growth opportunity (e.g., acquisition of Palamedrix) • The proteomics market has the potential to be as large or larger than the genomics market The mid-to-high-plex proteomics market is in • In our opinion, given its technology and brand, SLGC is well-positioned to capitalize on the growing its infancy, and SLGC will continue to benefit proteomics market 3 • Applications of proteomics are bearing significant fruit for SomaLogic’s customers today and show that from that tailwind proteomics is a burgeoning market with significant potential There is no operational downside to SLGC if it • The Company has the cash on hand to get to cash flow positive and realize value from its various R&D / does not consummate the Proposed Merger; Commercial initiatives SLGC is a scarce asset and can likely fetch a 4�� SomaLogic has a proprietary platform (technology, database, bioinformatics) that no other company can replicate and is still a potential acquisition candidate strong valuation in the future ___________________________________________________________ MADRYN ASSET MANAGEMENT 43 Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023.

1 SLGC’s Cost Savings Initiatives Are Expected to Generate ~$27mm in Run-Rate Operating Expense Savings By 2026 • When SLGC announced its SPAC transaction, the Company intended to not only focus on its core business, but also build substantial diagnostics and research businesses o Operating expenses spiraled out of control with little revenue growth, and, in response, the Company has re-focused on its core business while also curtailing costs • In 2022 and through 2023, management has worked to right size its cost structure o “And as we had talked about over the last couple of quarters, we have rightsized the organization. We've taken a significant amount of operating expenses out of the company over the last few months, focusing the company primarily on life sciences efforts.” – Roy Smythe (1/12/23) • The Merger Proxy discloses that LAB management believes SLGC will reduce operating expenditures by a further $27mm, while still growing revenue to $155mm; representing a decrease in operating expenditure margin from ~187% in 2023E to ~83% in 2026P Recent Relevant Management Commentary “We've made early progress, and this quarter's operating expenses reflect a 26% reduction over the same quarter last year. We are focusing our organization to preserve our substantial cash position and allow for operational flexibility into the future.” – Adam Taich, Q2 2023 Earnings Call (8/14/23) “I have continued confidence and positioning SomaLogic to increase revenue and improve margins while spending less capital” – Adam Taich, Q1 2023 Earnings Call (5/11/23) It is critical to say that while growth is important, we must manage the business efficiently and with more disciplined cash management. As stewards of shareholder capital, I'm committed to diligent spending, tight investment prioritization and commercial initiatives that deliver results consistently. – Adam Taich, Q4 2022 Earnings Call (3/28/23) I recognize that our balance sheet is one of our key assets, and I and the team will make sure to protect it. – Adam Taich, Q4 2022 Earnings Call (3/28/23) How does adding up to $300mm in debt and debt-like securities “protect” SLGC’s balance sheet? MADRYN ASSET MANAGEMENT 44 ___________________________________________________ Source: CapitalIQ, Company filings, transcripts, and Wall Street research.

1 SLGC Continues to Make Commercial Progress in a Tough Macroeconomic Environment Ahead of Its Distributed Kit Launch Recent Quarterly Performance • Despite a challenging macroeconomic environment, the Company has performed well given constrained biopharma and academic lab budgets • In 3Q:23, SLGC achieved revenue of $22 million, reflecting 14% year-over-year growth when excluding nonrecurring licensing revenue from the previous year’s quarter; product • The Company has significantly expanded its site of service business and revenue per quarter (distributed site of service solution) has nearly tripled YTD, growing will continue to grow in that channel from $1.1 in Q1:23 to $3.4 in Q3:23 with the expectation that it will continue to grow rapidly from here o The Company is on track to meet its expectation of doubling the number of authorized sites up and running to >16 by year-end o SLGC raised its full year 2023 revenue expectations to $82 million to $85 million from the prior range of $80 million to $84 million o Sites will begin to roll out 11K plex offering Despite the 2023 Headwinds, SLCG Has Seen Tremendous Recent Relevant Management Commentary Revenue Growth “Turning to progress in the quarter. Let me start with our core assay services offering, our largest revenue contributor in the near term. In recent quarters, we have taken steps to stabilize the business and position it for growth. Our commercial teams are intensely focused on new customer acquisition as well as driving high levels of customer retention.” – Adam Taich, Q2 2023 Earnings Call (08/14/23) “We continue to expand our reach into new biopharma accounts and are broadening the impact of the SomaScan platform well beyond our traditional discovery call points” – Adam Taich (08/14/23) “Equally important is the expansion of our distributed solution or Authorized Sites program. Since the full-scale launch of this program at the beginning of 2023, we have signed agreements with several partners to enable broader access of our technology, both domestically as well as into untapped international markets.” – Adam Taich (08/14/23) MADRYN ASSET MANAGEMENT 45 ___________________________________________________ Source: CapitalIQ, Company filings, transcripts, Wall Street research, and SomaLogic’s website, accessed as of 12/15/2023.

1 SLGC’s Pipeline Continues to Mature Positively • SomaLogic's SomaScan 11K Platform, showcasing an increase from 7,000 to 11,000 proteins, not only represents a significant leap in proteomics by covering over half the human proteome but also solidifies its technological leadership, offering unmatched protein measurement capabilities in the market • The Company's strategic partnerships with top-tier commercial and academic players like Novartis, Amgen, and Illumina, along with a robust operational deployment of its cutting-edge platform, emphasize SomaLogic’s strong market presence and validate its first-mover advantage in the proteomics industry • With the goal of ultimately measuring the entire proteome, SomaLogic is at the forefront of biomarker discovery, enhancing the precision of targeted healthcare therapies and contributing to the advancement of precision medicine through deeper insights into disease mechanisms and therapeutic responses • SomaLogic's commitment to continued innovation is further exemplified by the ongoing development of its distributed kit products, which mirrors the Olink commercial model and further bolsters the Company’s position as an industry leader and pioneer in the evolving field of proteomics SomaLogic Continues to Expand the Size and Universe of Its Measurable Proteins “Proteomics is a huge untapped opportunity set and a next frontier for drug discovery, research, and diagnostics. [SomaLogic] is a uniquely positioned company on that frontier and the one we see as leading the charge to deliver enormous value for researchers, clinicians and investors alike.” –Eli Casdin, SomaLogic Press Release, September 1, 2021 “This is a huge untapped opportunity set for Proteomics broadly but specifically for SomaLogic. No other company in the space is this far along or is really anywhere in the clinical market. ” The scalability enabled by SLGC’s aptamer-based approach will enable the –Eli Casdin, SomaLogic Investor Webcast, SomaScan Assay to continue to grow and approach measuring the entire proteome. March 29, 2021 MADRYN ASSET MANAGEMENT 46 ___________________________________________________ Source: CapitalIQ, Company filings, transcripts, Wall Street research, and SomaLogic’s website, accessed as of 12/15/2023.

1 Why Didn’t the Board Take the Search For New Management Seriously? How often do companies pursue a sale process with a temporary management team, when they have $450 million of cash and plenty of cash runway? • Permanent management is critical to drive long-term shareholder value, particularly with upcoming product launches and an ongoing strategic shift • The abrupt resignation of CEO Roy Smythe and the rapid appointment of Adam Taich as interim CEO left analysts perplexed o Adam Taich's prolonged interim title, despite no publicly disclosed active search for a permanent CEO, signals unclear strategic direction by the Board o The CFO role, filled temporarily by a consultant, indicates a more understandable short-term approach compared to the CEO's position • The Board's decision to not run a CEO search and not elevate Adam Taich to permanent CEO reflects their disregard for SLGC’s standalone prospects Priorities of the Board: New Board Member Appointments vs. Permanent Management Search “We felt interim [CEO] was simple as this was appropriate in the context of simultaneously bringing on 4 seasoned strategic leaders as new Board members.” “Interim CEO/CFO titles a bit confusing: It's been 4+ months and 2+ months since interim CEO Taich & CFO Lurier were - Troy Cox – Executive Chairman of SLGC Board appointed to their respective roles on interim bases. The CFO (filled by external consultant) status makes sense. But in the “Okay. So – I’m sorry, so he’s the full-time guy or you’re not conducting a simultaneous search in addition to case of the CEO role, Taich indicated there's no active search having Adam in the seat” underway & that he seems to have support of the Board. Unless, for example, there were other strategic considerations - Daniel Brennan – TD Cowen Research, Senior Tools & Diagnostics Analyst afoot, it's not clear why the interim CEO title is still necessary.” “In the near term, we're going to focus on onboarding our new Board members and empowering Adam to execute on our strategy.” - Troy Cox – Executive Chairman of SLGC Board - Jefferies – Brandon Couillard, 08/15/2023 SLGC Earnings Transcript, 03/28/2023 ___________________________________________________ MADRYN ASSET MANAGEMENT 47 Source: CapitalIQ, Company filings, transcripts, and Wall Street research.

Partnership With Illumina Will Give SLGC the Commercial Heft It Needs to 2 Properly Serve the Proteomics Market What Is the Partnership? What Do Analysts Think of the Partnership? • Most analysts were positive on the partnership, as shown in the example below: • On 12/31/21, SLGC partnered with ILMN to bring together ILMN’s genomics platform with SLGC’s proteomics platform in a major commercial arrangement to “[W]e believe that the partnership will allow each company to benefit from the better enable multi-omics research worldwide synergies between complementary modalities such as proteomics and genomics. We • In partnership, the companies will develop co-exclusive, co-branded, next- think the industry-leading capabilities of each company further bolster the value generation sequencing (NGS)-based proteomics products. This will enable generation potential of the partnership. Although it may take time for the partnership customers to run the SomaScan test on Illumina sequencers, opening up real time to pay meaningful dividends, we fully expect the companies to announce access to ~10,000 Illumina customers development milestones and launch goals in the time period leading up to o Illumina has an install base of 23,000 sequencers / 9500 customers in 155 commercialization. These should be important catalysts for each company over the (1) countries next few years, especially for SomaLogic given the materiality of the potential revenue contribution from the co-developed products.” • The partnership will leverage ILMN’s global installed base and commercial sales force (>17K sites, 70% of NGS market) – Kyle Mikson, Canaccord (01/05/22) • ILMN will pay SLGC $30mm up-front as well as royalty payments in each year following the first commercial sale of the co-developed products. In the fifth and What Is the Latest Timing Update and Are Customers each subsequent year following the first commercial sale, ILMN will pay a minimum annual royalty payment of $25.9mm to SLGC Excited? • At the time ILMN’s CTO said: • The kit product launch will begin with early access in 2024 and a full launch in 2025 “Proteins play a central role in cellular function and health, and NGS can “While attending the American Society of Human Genetics meeting in Washington, support a greater understanding of this role by unlocking biological insights at D.C. last week, I had the opportunity to speak to a number of prospective customers scale. We are committed to increasing the utility of NGS, and our partnership who are really excited about being able to leverage their Illumina NGS with SomaLogic will enable existing and future NGS customers to conduct instrumentation to gain deeper proteomic insights in their research. The energy even more sophisticated, high throughput multiomic studies.” around this effort is palpable, and the level of interest from customers is high.” – Adam Taich (11/08/2023) ___________________________________________________ Source: CapitalIQ, Company filings, transcripts, and Wall Street research. MADRYN ASSET MANAGEMENT 48 (1) Taken from Illumina’s website.

3 The Proteomics Market Has the Potential to be as Large or Larger Than the Genomics Market Analyst Quotes Market Over Slide from SPAC Transaction “We believe the field of next-gen proteomics tools is today akin to where genomics & DNA sequencing was in early-2000s.” – Initiation of Coverage, Jefferies 12/10/21 “SomaLogic is targeting the proteomics market, which we believe could be larger than the genomics market (we estimate the NGS market could be $25-50 billion).” – Kyle Mikson, Initiation of Coverage, Canaccord 12/14/21 “Overall, we believe proteomics (including the high-plex segment) is not a winner-take- all market, and it should be large enough for platforms with different specializations to achieve strong market share.” – Kyle Mikson 12/14/2022 Company Quotes SomaLogic Well Positioned to Capture Upside “The total addressable market for proteomics will approach $100 billion over the next several • Given its technology and brand, SLGC is well-positioned to capitalize on the growing years. It includes a current $50 billion life sciences tools component represented by biopharma proteomics market translational academic institutes, and emerging diagnostics opportunity, which over the next few years -- several years should grow to more than $40 billion. This is an opportunity with o More than 700 peer-reviewed publications demonstrating the power of the clear parallels to the early growth years of genomics.” SomaScan platform have been published, with over 450,000 samples tested since 2010, the technology is protected by over 600 patents – Roy Smythe, 11/15/21 “We have known SomaLogic for a long time but became investors last year when we led their o Elite customer relationships with over 185 customers, including nine of the Series A. It is always a little bit interesting to call it a Series A when you are investing in a top 20 biopharmaceutical companies company that’s 20 years old and had about $500M already invested in it. And what we saw, as we had seen early on in the field of genomics, the maturation of a field of proteomics that has • Applications of proteomics are bearing significant fruit for SomaLogic’s customers an order of magnitude bigger potential to impact human life and we’ve been looking for a today and show that proteomics is a burgeoning market with significant potential dominant platform company that could not only bridge the enablers but also take the (e.g., Novo Nordisk extended its collaborative agreement with SLGC; management information and data base of proteomics and leverage it into clinical applications” called out GLP-1 agonists as driving increased interest in SomaScan) – Eli Casdin, 3/29/21 MADRYN ASSET MANAGEMENT 49 ___________________________________________________ Source: CapitalIQ, Company filings, transcripts, Wall Street research, and SomaLogic’s website, accessed as of 12/15/2023.

4 The Company Has the Cash On Hand to Get to Cash Flow Positive and Realize Value From Its Various R&D / Commercial Initiatives Revenue ($ in millions) $500 • SLGC management expresses continued confidence in its $404 $368 $400 $331 core business and its future prospects $295 $261 $300 $228 $198 $170 $200 $143 o “I would say most of the time we're seeing fantastic $106 $85 $100 growth in both customer segments, but we're really $0 starting to accelerate and penetrate more deeply in the 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 biopharma.” – Adam Taich, interim CEO, Nov. 8, 2023 Unlevered FCF ($ in millions) o “We are reiterating our 2023 revenue guidance of $80 $200 $146 million to $84 million. We continue to see 2023 as a $150 $106 building year for the organization while our teams $100 $72 $43 worked diligently on the many growth drivers ahead. – $50 $19 $1 2023 2024 2025 2026 2027 Eliot M. Lurier, former interim CFO, Aug. 15, 2023 $- 2028 2029 2030 2031 2032 2033 $(19) $(50) $(40) • SomaLogic’s projections disclosed in the Merger Proxy reflect $(65) $(100) its expectations that SomaLogic’s growth will continue $(106) $(150) $(138) unabated and its financial profile will improve $(200) • SomaLogic has the runway to achieve this plan Forecasted Year End Cash Balance ($ in millions) $559 $600 $500 $413 $402 $400 $307 $296 $300 $235 $231 $191 $192 $172 $173 $200 $100 $0 ___________________________________________________________ 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Source: SomaLogic management projections per Merger Proxy. CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023. MADRYN ASSET MANAGEMENT 50 Note: Forecasted cash balance represents 2022 year end actual cash and cash equivalents plus short-term investments. Subsequent years are projected by incorporating SomaLogic management’s unlevered FCF projections, per Merger Proxy.

4 SomaLogic Has A Proprietary Platform That No Other Company Can Replicate ✓ A proprietary platform (technology, database, bioinformatics) and a first-mover advantage ✓ 20 years of experience, and more than $500mm+ total investment in pre-SPAC technology ✓ More evolutionarily advanced position (enablement and applications) than any other proteomics company ✓ Market validated – many customers, established products, revenue and more of each assured ✓ The global leader in protein measurement, at 2.0x all competitors – 11,000 current ✓ The world’s largest clinical proteomics database ✓ The market leader in protein bioinformatics – 1bn+ protein measurements and 15mm+ clinical data points ✓ Core measurement reagent is nucleic acid, with significant technology trajectory options ✓ Valuable commercial Illumina partnership ___________________________________________________________ MADRYN ASSET MANAGEMENT 51 Source: CapitalIQ, Company filings, Press Releases, and FactSet as of 12/15/2023.

Rejecting the Proposed Merger Is Consistent With Past Shareholder Decisions and Proxy Advisory Recommendations Proposed Merger Reason for rejection • Valuation represents a meaningful discount to historical trading multiples • There are conflicts of interest inherent in a transaction with an affiliate of a large shareholder Diversified Healthcare Trust - Office Properties Income Trust • The boards’ Transaction Committees were not fully independent • The boards did not protect shareholders against the foreseeable post-announcement decline in the acquirers’ Monmouth Real Estate Investment - Equity Commonwealth shares • Merger consideration is uncompelling relative to the standalone scenario • Proxy statement projections appear overly conservative relative to recent management commentary • Timing of deal raises concern that the consideration doesn’t reflect pending upside catalysts Extended Stay America - Blackstone and Starwood Consortium MADRYN ASSET MANAGEMENT 52

Vote AGAINST the Proposed Merger PROTECT YOUR INVESTMENT IN SLGC We Urge Shareholders to Vote AGAINST the Proposed Merger www.NoSomaLogicMerger.com MADRYN ASSET MANAGEMENT 53

Thank You